`
`
`Filed On Behalf Of:
`Novartis Pharmaceuticals Corporation
`
`By:
`Nicholas N. Kallas
`nkallas@Venable.com
`(212) 218-2243
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`BIOCON PHARMA LIMITED,
`Petitioner,
`
`v.
`
`NOVARTIS PHARMACEUTICALS CORPORATION,
`Patent Owner.
`
`
`Case IPR2020-01263
`Patent 8,101,659
`
`
`
`PATENT OWNER’S MANDATORY NOTICES
`UNDER 37 C.F.R. § 42.8(a)(2)
`
`
`
`
`
`
`
`
`
`
`
`REAL PARTY-IN-INTEREST PURSUANT TO 37 C.F.R. § 42.8(b)(1)
`
`Novartis Pharmaceuticals Corporation (“Novartis”) owns U.S. Patent No.
`
`8,101,659 (“the ’659 Patent”) and is a wholly-owned subsidiary of Novartis AG.
`
`Novartis is the real party-in-interest in IPR2020-01263.
`
`RELATED MATTERS PURSUANT TO 37 C.F.R. § 42.8(b)(2)
`
`The ’659 Patent has been or is at issue in the following judicial proceedings:
`
`(1) In Re: Entresto (Sacubitril/Valsartan) Patent Litig., No. 20-md-2930-LPS; (2)
`
`Novartis Pharm. Corp. v. Alkem Labs. Ltd., et al., No. 19-cv-1979-LPS (D. Del.);
`
`(3) Novartis Pharm. Corp. v. Alembic Pharm. Ltd., et al., No. 19-cv-2021-LPS (D.
`
`Del.); (4) Novartis Pharm. Corp. v. Dr. Reddy’s Labs., Inc., et al., No. 19-cv-2053-
`
`LPS (D. Del.); (5) Novartis Pharm. Corp. v. Alembic Pharm. Ltd., et al., No. 20-
`
`cv-74-LPS (D. Del.); (6) Novartis Pharm. Corp. v. Lupin Atlantis Holdings, S.A.,
`
`et al., No. 20-cv-415-LPS (D. Del.); (7); Novartis Pharm. Corp. v. Mylan Pharm.
`
`Inc., et al., No. 20-cv-445-LPS (D. Del.); (8) Novartis Pharm. Corp. v. Mylan
`
`Pharm. Inc. et al., No. 19-cv-201-IMK (N.D.W. Va.); and (9) Novartis Pharm.
`
`Corp. v. Macleods Pharm. Ltd., et al., No. 19-cv-19345 (D.N.J.) (dismissed).
`
`IDENTIFICATION OF LEAD AND BACK-UP COUNSEL
`PURSUANT TO 37 C.F.R. §§ 42.8(b)(3) and 42.10(a)
`
`Novartis designates Nicholas N. Kallas (Reg. No. 31,530) as lead counsel
`
`and Christina Schwarz (Reg. No. 78,484) as back-up counsel.
`
`A power of attorney from Novartis is being submitted with this Notice.
`1
`
`
`
`
`
`SERVICE INFORMATION PURSUANT TO 37 C.F.R. § 42.8(b)(4)
`
`Novartis may be served electronically using the following e-mail address:
`
`nkallas@Venable.com
`
`Novartis may be served by postal mailing, hand-delivery, telephone or
`
`facsimile as follows:
`
`Nicholas N. Kallas
`Venable LLP
`1290 Avenue of the Americas
`New York, NY 10104
`Telephone: (212) 218-2243
`Facsimile: (212) 218-2200
`
`
`
`
`
`/ Nicholas N. Kallas /
`Nicholas N. Kallas
`Registration No. 31,530
`
`
`
`2
`
`
`Respectfully submitted,
`
`Dated: August 27, 2020
`
`
`
`
`
`
`
`CERTIFICATE OF SERVICE
`
`I certify that a copy of Patent Owner’s Mandatory Notices Under 37 C.F.R.
`
`§ 42.8(a)(2) was served on August 27, 2020 by causing it to be sent by email to
`
`counsel for Petitioner at the following email addresses:
`
`Christopher Ferenc (christopher.ferenc@katten.com)
`
`Brian Sodikoff (brian.sodikoff@katten.com)
`
`Dated: August 27, 2020
`
`
`
`
`
`/ Nicholas N. Kallas /
`Nicholas N. Kallas
`Registration No. 31,530
`
`
`
`3
`
`